Abstract | BACKGROUND: OBJECTIVE: Initiated by the results of this pilot study, we have specifically designed a study to test the hypothesis that cis-9, trans-11 conjugated linoleic acid improves LDL phenotype in moderately overweight subjects with LDL phenotype B. Effects on the serum lipid profile, on plasma glucose and insulin concentrations, and on clinical parameters were also examined. DESIGN: Volunteers with LDL phenotype B were divided into three groups consuming daily a drinkable dairy product not enriched with CLA (placebo, n = 34), the same dairy product enriched with 3g c9, t11 CLA (n = 34), or the dairy product enriched with 3g t10, c12 CLA (n = 19) for 13 weeks. RESULTS: CONCLUSIONS: In humans with LDL phenotype B, c9, t11 CLA and t10, c12 CLA do not beneficially change risk factors for cardiovascular disease or diabetes.
|
Authors | Elke Naumann, Yvon A Carpentier, Asgeir Saebo, Taous S Lassel, Jean-Michel Chardigny, Jean-Louis Sébédio, Ronald P Mensink, FunCLA Study Group |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 188
Issue 1
Pg. 167-74
(Sep 2006)
ISSN: 0021-9150 [Print] Ireland |
PMID | 16289507
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Insulin
- Linoleic Acids, Conjugated
- Lipoproteins
- Lipoproteins, LDL
|
Topics |
- Adult
- Aged
- Blood Glucose
(drug effects)
- Cardiovascular Diseases
(prevention & control)
- Female
- Humans
- Insulin
(blood)
- Linoleic Acids, Conjugated
(administration & dosage)
- Lipoproteins
(blood)
- Lipoproteins, LDL
(blood)
- Male
- Middle Aged
- Overweight
- Risk Factors
|